Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Timolol for Healing Lower Extremity Wounds after Mohs Surgery
NCT06941467Phase 1Recruiting
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of timolol maleate gel + placebo in open wound (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Wound surface area healing (skin reepithelialization) at 12 weeks. Started Jan 2025; status: recruiting.
02
Drugs
timolol maleate gel + placebo
03
Conditions
open wound
Beyond the preview
Go deeper on NCT06941467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06941467.